High concentration antibody-containing liquid formulation
US11359026B2 · kind B2 · utility
1Cited by
75References
2Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 27, 2021 |
| Grant date | Jun 14, 2022 |
| Priority date | — |
| Expiry date | Apr 27, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.